|
|
Post by mnkdd on Aug 26, 2013 17:38:14 GMT -5
Some "analyst" said difference in incidence of coughing between Gen2 and MedTone arms was stat. sig.
Is this true? I haven't seen any data supporting this. Is it safe to file this away as BS?
|
|
|
|
Post by mnkdd on Aug 26, 2013 18:49:40 GMT -5
Read the FAQ, but no mention of coughing.
|
|
|
|
Post by notamnkdmillionaire on Aug 26, 2013 20:28:23 GMT -5
mnkdd,
The cough issue has been addressed and I can only assume that MNKD doesn't feel it's worthy to discuss as they clearly stated it was a non productive cough lasting no longer than a week before it went away. There is no data that we know of to suggest it lingered for longer than that. Many want to use this cough issue as some big reason why Afrezza is worth being approved. They are grasping at straws. Just look at the side effects of so many popular diabetes drugs and compare it to the Afrezza's one week max cough. It doesn't seem to be an issue and I don't think the FDA believes it's a big issue either. We'll find out soon enough in ~4-6 months.
|
|
|
|
Post by BD on Aug 26, 2013 20:39:12 GMT -5
The FDA would most likely not have recommended testing on 4-year-olds if they had had pulmonary concerns...IMO.
|
|
